Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of PRO 140 for Prophylaxis of Acute Graft-Versus-Host Disease in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Hematopoietic Cell Transplantation.
Phase of Trial: Phase II
Latest Information Update: 04 Feb 2017
At a glance
- Drugs PRO 140 (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors CytoDyn
- 14 Dec 2016 Status changed from not yet recruiting to recruiting.
- 12 Apr 2016 Status changed from planning to not yet recruiting.
- 21 Oct 2015 New trial record